mRNA 1944
Alternative Names: mRNA encoding Chikungunya antibody; mRNA-1944Latest Information Update: 28 Dec 2021
Price :
$50 *
At a glance
- Originator Moderna Therapeutics
- Class Antibodies; Antivirals; Monoclonal antibodies; RNA
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Chikungunya virus infections
Most Recent Events
- 28 Dec 2021 Discontinued - Phase-I for Chikungunya virus infections (Prevention) in USA (IV) (Moderna Therapeutics pipeline, December 2021)
- 28 Sep 2020 mRNA 1944 is available for licensing as of 28 Sep 2020. https://www.modernatx.com/
- 17 Sep 2020 Updated adverse events data from a phase I trial in Chikungunya virus infections released by Moderna Therapeutics